prasinezumab
mAbexperimental
Clinical trial activity
5 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Jun 27, 2017 (NCT03100149)
Timeline
Indications
Mechanism of action
- Alpha-synucleinBINDING AGENT
Alpha-synuclein binding agent
- Alpha-synucleinINHIBITOR
SNCA inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4298077 ↗
Also known as
- ro7046015
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07174310 | Phase 3 | Dec 31, 2025 | Prothena Biosciences Inc, Roche |
| NCT07055087 | Phase 2 | Dec 31, 2025 | University of Tuebingen |
| NCT06659653 | Early Phase 1 (Phase 1) | May 24, 2024 | Shenzhen Pregene Biopharma Co., Ltd., The First People's Hospital of Jingzhou |
| NCT04777331 | Phase 2 | May 5, 2021 | Prothena Biosciences Inc, Roche |
| NCT03100149 | Phase 2 | Jun 27, 2017 | Prothena Biosciences Inc, Roche |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Prothena Biosciences Inc | For profit | 3 | 0 | 2 | 2017 |
| Roche | For profit | 3 | 3 | 2 | 2017 |
| Shenzhen Pregene Biopharma Co., Ltd. | For profit | 1 | 0 | 1 | 2024 |
| The First People's Hospital of Jingzhou | Academic/Hospital | 1 | 1 | 1 | 2024 |
| University of Tuebingen | Academic/Hospital | 1 | 1 | 1 | 2025 |
5 organizations
Page 1 / 1